Attached files
file | filename |
---|---|
8-K - FORM 8-K - Osteologix, Inc. | c94244e8vk.htm |
EX-10.2 - EXHIBIT 10.2 - Osteologix, Inc. | c94244exv10w2.htm |
EX-10.1 - EXHIBIT 10.1 - Osteologix, Inc. | c94244exv10w1.htm |
Exhibit 99.1
Osteologix, Inc. 4415 Cox Road Glen Allen, Virginia 23060 |
Press Release
Osteologix Announces Financing
Glen Allen, VA, January 4, 2010 Osteologix, Inc. (OTCBB: OLGX) today announced that it has
entered into a securities purchase agreement for a $1 million private placement of its common
stock.
On December 29, 2009, Osteologix entered into a securities purchase agreement with Nordic Biotech
Opportunity Fund K/S, an affiliate of Nordic Biotech K/S, the Companys largest shareholder, for
the sale of 1,992,448 shares of common stock for an aggregate purchase price of $1,000,000, or
approximately $0.5019 per share, the 10-day volume weighted average closing price of Osteologixs
common stock as of the end of trading on December 28, 2009, and a related registration rights
agreement. Osteologix expects the financing, which is a private placement exempt from registration
under the Securities Act of 1933, to close on or about January 7, 2010, subject to satisfaction of
certain customary closing conditions.
In connection with the financing John M. Barberich was appointed a director and Chairman of
the Board of Directors of the Company on December 29, 2009. Mr. Barberich has been a consultant to
biotech related companies since 2003 and since September 2005 has been a Financial Advisor to
Nordic Biotech Advisors ApS, a firm that provides investment advisory services to Nordic Biotech
K/S and Nordic Biotech Opportunity Fund, security holders in the Company. Prior to 2003, Mr.
Barberich served as Vice President and Chief Financial Officer of three biopharmaceutical
companies: Omrix Biopharmaceuticals (now part of Johnson & Johnson), Scriptgen Pharmaceuticals (now
known as Anadys Pharmaceuticals) (NASDAQ: ANDS) and ACADIA Pharmaceuticals (NASDAQ: ACAD).
Concurrent with the Mr. Barberichs appointment, Christian Hansen, Florian Schönharting and
Christopher B. Wood resigned as directors. Nordic Biotech retains the right to appoint two
additional board members.
Christian Hansen, Partner of Nordic Biotech stated, Nordic Biotech is fully committed to
Osteologix and we are very pleased with advances at the Company.
The foregoing description of the financing is only a summary and is qualified in its entirety by
reference to the securities purchase and registration rights agreements, copies of which are filed
as exhibits Osteologixs Current Report on Form 8-K, filed today with the SEC.
The securities sold and issued in connection in the financing have not been registered under the
Act or any state securities laws and may not be offered or sold in the United States absent
registration with the SEC or an applicable exemption from the registration requirements.
Osteologix, Inc. 4415 Cox Road Glen Allen, Virginia 23060 |
Press Release
About Osteologix
Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for
the treatment and prevention of diseases of bone and joint tissues. Its lead product candidate, NB
S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. Osteologix
has completed a Phase II clinical trial of NB S101 that demonstrated the ability of NB S101 to
reduce markers of bone resorption and increase bone mineral density and also included a comparison
of NB S101 (strontium malonate) to Proteolos (strontium renalate) marketed by Les Labortories
Servier. Osteologixs strategy is to develop its once-daily strontium tablet for the osteoporosis
market by entering into Development and Marketing partnerships with regional or global
pharmaceutical companies. The Company currently believes that they should be able to obtain
regulatory approval and launch the product in Europe in early 2012, and on a later date in the
United States and Japan.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
the anticipated closing of the financing described in this press release, and statements about the
potential development of NB S101, Osteologixs ability to enter into development and marketing
partnerships or the ability of the company or its development partners to obtain regulatory
approval. These forward-looking statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected or assumed in such forward-looking
statements, including, without limitation, uncertainties about the closing of the financing, our
ability to raise sufficient capital to continue development of NB S101; our ability to enter into
development and marketing partnership agreements with third parties or of such third parties to
obtain regulatory approval for NB S101; our or any third party licensees ability to reach
agreement with the United States Food & Drug Administration regarding the design of our Phase III
clinical trials for NB S101; our ability to conduct and successfully complete clinical trials of NB
S101 and obtain approval to market this product; potential success and introduction of competing
products; effectiveness of our efforts to protect our intellectual property rights; decisions made
by holders of third party patent rights; listing standards of national stock exchanges; general
economic conditions; changes in government regulations and administrative procedures; changes in
our business strategy; fluctuations of interest rates and credit markets. Additional factors that
could cause actual results to differ materially are included under the heading Risk Factors in
Part I, Item 1A of our Annual Report on Form 10-K. All forward-looking statements and risk factors
included in this document are made as of the date hereof, based on information available to us as
of the date hereof, and we assume no obligation to update any forward-looking statement or risk
factor. You should consult the risk factors listed in our Annual Report on Form 10-K and from time
to time in our Quarterly Reports on Form 10-Q.
###
Contact:
Baxter Phillips, III
804.747.6026
804.747.6026